Posner Christopher

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
14
Insider Sells Sum
$421,804.77

Insider Activity of Posner Christopher

According to the SEC Form 4 filings, Posner Christopher, being in a position of

  1. PRESIDENT AND CEO at Cara Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 58271 share for $35,822,
    over all time since 2020-11-19, has bought 0 shares, and sold 97405 shares for $421,805.

The largest sale of all time was on 2022-11-16 and amounted to 14470 shares of Cara Therapeutics, Inc. for $161,051.

Biography of Posner Christopher

No biography is available at this moment.

2024-08-01SaleCara Therapeutics, Inc.
CARA
PRESIDENT AND CEO
4,149
0.0075%
$0.35$1,452-9.22%
2024-05-02SaleCara Therapeutics, Inc.
CARA
PRESIDENT AND CEO
3,936
0.007%
$0.75$2,952-54.55%
2024-02-29SaleCara Therapeutics, Inc.
CARA
PRESIDENT AND CEO
5,834
0.0115%
$0.89$5,192-21.05%
2024-02-08SaleCara Therapeutics, Inc.
CARA
PRESIDENT AND CEO
35,575
0.0607%
$0.53$18,855+29.08%
2024-02-01SaleCara Therapeutics, Inc.
CARA
PRESIDENT AND CEO
4,981
0.0088%
$0.55$2,740+17.13%
2023-11-02SaleCara Therapeutics, Inc.
CARA
President and CEO
3,796
0.0072%
$1.22$4,631-43.46%
2023-08-03SaleCara Therapeutics, Inc.
CARA
President and CEO
4,307
0.0077%
$3.07$13,222-72.76%
2023-05-05SaleCara Therapeutics, Inc.
CARA
President and CEO
3,869
0.0072%
$4.40$17,024-71.98%
2023-03-03SaleCara Therapeutics, Inc.
CARA
President and CEO
5,987
0.0105%
$9.71$58,134-76.65%
2023-02-02SaleCara Therapeutics, Inc.
CARA
President and CEO
4,191
0.0077%
$11.80$49,454-75.9%
2022-11-16SaleCara Therapeutics, Inc.
CARA
President and CEO
14,470
0.0268%
$11.13$161,051-65.8%
2022-04-04SaleCara Therapeutics, Inc.
CARA
President and CEO
2,006
0.0038%
$12.67$25,416-20.22%
2021-06-07SaleCara Therapeutics, Inc.
CARA
director
2,304
0.0045%
$13.04$30,044-6.38%
2020-11-19SaleCara Therapeutics, Inc.
CARA
director
2,000
0.0042%
$15.82$31,638-5.37%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.